YAP1 and hepatocellular carcinoma: Furthermore, a similar improvement in ASO activity with GalNAc conjugation was observed in DEN plus CCl4-induced HCC, where a comparable reduction in YAP1, a transcriptional coactivator frequently activated in HCC,21 was achieved by GalNAc-conjugated YAP1 ASO at one-tenth of a dose of the unconjugated ASO (5 mg/kg versus 50 mg/kg) (Figure S4), suggesting that GalNAc conjugation might be effective even in advanced HCC with high tumor burden.